Afsheen N. Iqbal

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

Adam J. Schoenfeld, Kathryn C. Arbour, Hira Rizvi et al. · Annals of Oncology · 2019 · 401 citations · Full text

Clinical Immunology, Autoimmune Disease, Immunology +9

COVID-19 in patients with lung cancer

Jie Luo, Hira Rizvi, Isabel R. Preeshagul et al. · Annals of Oncology · 2020 · 267 citations · Full text

Medicine, Covid-19 Pandemic, Covid-19 Epidemiology +3

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

Justin Jee, Emily S. Lebow, Randy Yeh et al. · Nature Medicine · 2022 · 170 citations · Full text

Tumor Dna-guided Therapy, Overall Survival, Medicine +7

Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes

Jarushka Naidoo, Maria L. Santos-Zabala, Tunç Iyriboz et al. · Clinical Lung Cancer · 2016 · 161 citations · Full text

Medicine, Clinico-pathologic Features, Neuroendocrine Disorder +8

Induced remote ischemic pre-conditioning on ischemia-reperfusion injury in patients undergoing coronary artery bypass.

Nasir Ali, Farwa Rizwi, Afsheen N. Iqbal et al. · PubMed · 2010 · 82 citations